INICIO

Continuation of the Revista Mexicana de Cardiología

  • Home
  • Instructions for authors
    • Instructions for authors
    • Regulations for the publication of supplements
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • About Us
    • About the Journal            
    • Publisher Policies
    • Previous Titles
    • Editorial Management
  • Contact





2022, Number 2

Cardiovasc Metab Sci 2022; 33 (2)

Case report: COVID-19 mRNA vaccine association with acute myocarditis

Pérez-Orpinel, Oscar A; Figuerola-Chaparro, Luis C; Fernández-Rosas, Susana; Moreno-Zamudio, Daniela; Mendoza-González, Celso A

ABSTRACT

A 50-year-old woman presented to the Emergency Department with chest pain, the elevation of cardiac enzymes, and no electrocardiographic alterations. Coronary angiography was performed in which no obstructive lesions were found. A cardiac magnetic resonance study reported an image consistent with acute myocarditis without evidence of myocardial ischemia. The patient received the first dose of Pfizer-BioNTech vaccine two days before the onset of symptoms. In most cases of myocarditis, its clinical manifestations lie in a wide spectrum, and the etiological diagnosis is indeterminate. In recent months, the probable association between cases of myocarditis with COVID-19 mRNA vaccines has been established. The use of the COVID-19 mRNA vaccine has demonstrated significant benefits in reducing morbidity and mortality related to SARS-CoV-2 virus infection. This event may be a transitory process that does not represent a contraindication for the application of the vaccine.
  FULL TEXT PDF   FLIPBOOK

Keywords

Acute myocarditis COVID-19 mRNA vaccine ESAVI




  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5
  • WHO 2025 HIV guideline: Integrating cardiometabolic care into HIV services
    2026, Vol.37, Núm. 1
  • The 2026 Mexican Consensus on Arterial Hypertension: Expert Group on Arterial...
    2026, Vol.37, Núm. 1
  • Clinical features, echocardiographic findings and surgical aspects related to...
    2026, Vol.37, Núm. 1
  • The triglyceride-glucose index and its usefulness in clinical practice as a...
    2026, Vol.37, Núm. 1
  • Challenges in Mexico in the management of out-of-hospital cardiac arrest
    2026, Vol.37, Núm. 1
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3


Cardiovascular and Metabolic Science Vol. 33, Num. 2, Abril-Junio 2022. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 http://www.medigraphic.com/cms ancam@ancam.org.mx https://www.medigraphic.com/cms/ E-mail: revmexcardiol@gmail.com Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-022717130200-102. ISSN impreso: 2683-2828, ISSN electrónico: 2954-3835. Otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 9 de abril de 2026.

 

2026     |     https://www.cardiovascularandmetabolicscience.org.mx/